{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:26:11Z","timestamp":1789935971468,"version":"4.0.1"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The objective of the present study was to evaluate whether cefpirome, a member of the latest class of broad-spectrum cephalosporins, sufficiently penetrates subcutaneous adipose tissue in septic patients. After the administration of the drug at 2 g, tissue cefpirome concentrations in septic patients (\n            <jats:italic>n<\/jats:italic>\n            = 11) and healthy controls (\n            <jats:italic>n<\/jats:italic>\n            = 7) were determined over a period of 4 h by means of microdialysis. To assess the antibacterial effect of cefpirome at the target site, the measured pharmacokinetic profiles were simulated in vitro with select strains of\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            and\n            <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n            . The tissue penetration of cefpirome was significantly impaired in septic patients compared with that in healthy subjects. For subcutaneous adipose tissue, the area under the concentration-versus-time curve values from 0 to 240 min were 13.11 \u00b1 5.20 g\u2009\u00b7\u2009min\/liter in healthy subjects and 6.90 \u00b1 2.56 g\u2009\u00b7\u2009min\/liter in septic patients (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). Effective bacterial growth inhibition was observed in all in vitro simulations. This was attributed to the significantly prolonged half-life in tissue (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05), which kept the tissue cefpirome levels above the MICs for relevant pathogens for extended periods in the septic group. By consideration of a dosing interval of 8 h, the values for the time above MIC (\n            <jats:italic>T<\/jats:italic>\n            &gt; MIC) in tissue were greater than 60% for pathogens for which the MIC was \u22644 mg\/liter in all septic patients. The present data indicate that cefpirome is an appropriate agent for the treatment of soft tissue infections in septic patients. However, due to the high interindividual variability of the pharmacokinetics of cefpirome in tissue, dosing intervals of not more than 8 h should be preferred to ensure that susceptible bacterial strains are killed in each patient.\n          <\/jats:p>","DOI":"10.1128\/aac.49.2.650-655.2005","type":"journal-article","created":{"date-parts":[[2005,1,26]],"date-time":"2005-01-26T22:04:40Z","timestamp":1106777080000},"page":"650-655","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":48,"title":["Pharmacokinetics and Pharmacodynamics of Cefpirome in Subcutaneous Adipose Tissue of Septic Patients"],"prefix":"10.1128","volume":"49","author":[{"given":"Robert","family":"Sauermann","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Delle-Karth","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Intensive Care Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Marsik","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard X.","family":"Mayer-Helm","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Georgopoulos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Infectious Diseases and Chemotherapy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Mu\u0308ller","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Joukhadar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics"},{"name":"Department of Internal Medicine I, Division of Infectious Diseases and Chemotherapy"},{"name":"Institute of Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0732-8893(99)00106-6","volume":"35","year":"1999","unstructured":"Biedenbach, D. J., D. M. Johnson, R. N. Jones, et al. 1999. In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. Diagn. Microbiol. Infect. Dis.35:299-305.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0732-8893(99)00098-X","volume":"35","year":"1999","unstructured":"Biedenbach, D. J., M. T. Lewis, R. N. Jones, et al. 1999. In vitro evaluation of cefepime and other broad-spectrum beta-lactams for isolates in Malaysia and Singapore medical centers. Diagn. Microbiol. Infect. Dis.35:277-283.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.101.6.1481"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.1.133"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.733"},{"key":"e_1_3_2_8_2","unstructured":"European Agency for the Evaluation of Medicinal Products. 2002. Guideline for good clinical practice. ICH Topic E6. [Online.] http:\/\/www.emea.eu.int\/pdfs\/human\/ich\/013595en.pdf\n."},{"key":"e_1_3_2_9_2","first-page":"1","volume":"29","year":"1992","unstructured":"Hancock, R. E., and F. Bellido. 1992. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. J. Antimicrob. Chemother.29(Suppl. A):1-6.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/ajrccm.165.2.2106082","volume":"165","year":"2002","unstructured":"Herkner, H., M. R. Muller, N. Kreischitz, B. X. Mayer, M. Frossard, C. Joukhadar, N. Klein, E. Lackner, and M. Muller. 2002. Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. Am. J. Respir. Crit. Care Med.165:273-276.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1067\/mcp.2000.104266","volume":"67","year":"2000","unstructured":"Hollenstein, U., M. Brunner, B. X. Mayer, S. Delacher, B. Erovic, H. G. Eichler, and M. Muller. 2000. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers. Clin. Pharmacol. Ther.67:229-236.","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_3_2_12_2","first-page":"143","volume":"28","year":"1995","unstructured":"Hyatt, J. M., P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. 1995. The importance of pharmacokinetic\/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet.28:143-160.","journal-title":"Focus on antibacterial agents. Clin. Pharmacokinet."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200102000-00030"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200207000-00013"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jac\/22.6.911","volume":"22","year":"1988","unstructured":"Kavi, J., J. M. Andrews, J. P. Ashby, G. Hillman, and R. Wise. 1988. Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin. J. Antimicrob. Chemother.22:911-916.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.1997"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00120-0"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000077077.54084.B0"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001340000741"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00466-2"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/(SICI)1522-2683(20000501)21:8<1558::AID-ELPS1558>3.0.CO;2-N","volume":"21","year":"2000","unstructured":"Mayer, B. X., U. Hollenstein, M. Brunner, H. G. Eichler, and M. Muller. 2000. Micellar electrokinetic chromatography for the analysis of cefpirome in microdialysis and plasma samples obtained in vivo from human volunteers. Electrophoresis21:1558-1564.","journal-title":"Electrophoresis"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.369-377.2004"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1441-1453.2004"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2703"},{"key":"e_1_3_2_25_2","unstructured":"National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00243-0"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jac\/41.4.443","volume":"41","year":"1998","unstructured":"Pierard, D., K. Emmerechts, S. Lauwers, et al. 1998. Comparative in-vitro activity of cefpirome against isolates from intensive care and haematology\/oncology units. J. Antimicrob. Chemother.41:443-450.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.122526"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/514622"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2796.2003.01141.x","volume":"253","year":"2003","unstructured":"Verhave, J. C., C. P. Balje-Volkers, H. L. Hillege, D. de Zeeuw, and P. E. de Jong. 2003. The reliability of different formulae to predict creatinine clearance. J. Intern. Med.253:563-573.","journal-title":"J. Intern. Med."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.5.1248"},{"key":"e_1_3_2_32_2","first-page":"117","volume":"54","year":"1997","unstructured":"Wiseman, L. R., and H. M. Lamb. 1997. Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs54:117-140.","journal-title":"A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs"},{"key":"e_1_3_2_33_2","unstructured":"World Medical Association. 6 October 2002. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. [Online.] http:\/\/www.wma.net\/e\/policy\/b3.htm\n."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3548-3553.2003"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.2.650-655.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.2.650-655.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:49:13Z","timestamp":1645469353000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.2.650-655.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1128\/AAC.49.2.650-655.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.2.650-655.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"2004-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-10-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}